Learning Objectives:

By the end of this session, participants will be able to:

1) Explain a PK-PD relationship

2) Describe the pharmacokinetics and pharmacodynamics of hydroxychloroquine
3) Evaluate recent literature regarding the PK-PD relationship of hydroxychloroquine in lupus
4) Critically appraise a clinical pharmacology study for hydroxycloroquine in pediatric lupus patients at Duke

Speaker Name: 
Stephen Balevic, MD
Duke South 3rd Floor Conference Room (purple zone)
200 Trent Drive
Durham, NC 27710
United States
Room Number: 
Session date: 
Tuesday, April 26, 2016 - 8:00am to 9:00am
  • 1.00 AMA PRA Category 1 Credit(s)

Please login or register to take this course.